In the pharmaceutical industry, digitalization is never just about stacking “efficiency tools”—it is closely tied to drug quality, patient safety, and regulatory compliance. Every stage, from drug R&D and clinical trials to manufacturing and distribution, is strictly governed by GxP regulations (GMP, GLP, GCP, etc.), which impose extremely high requirements on data integrity, audit trails, and access control.
However, in real office and R&D environments, problems such as uncontrolled endpoint security, unvalidated software, difficult-to-trace data exfiltration, and loose permission management remain widespread. These seemingly “endpoint-level” details can become the trigger for audit failures, data breaches, or even drug quality incidents.
So how can pharmaceutical companies achieve integrated endpoint and data security while meeting stringent compliance requirements? Let’s start with a real-world scenario.
Scenario: Endpoint Security Weaknesses Exposed During a GMP Audit
A mid-sized pharmaceutical company operates an R&D center, quality control laboratories, production workshops, and multiple functional departments, with hundreds of endpoint devices. Its business systems include LIMS, ERP, electronic lab notebooks (ELN), chromatography data systems (CDS), and more.
During a GMP audit, auditors identified the following issues:
- Some laboratory workstations had unvalidated software installed, and even cracked tools were present, with no software validation documentation available.
- Endpoints used for electronic records lacked a unified audit trail, making it impossible to confirm whether critical data had been tampered with.
- Employees could copy raw experimental data and formulation files to USB storage devices and take them off-site, with no way for IT to trace the actions.
- The R&D network and office network were not effectively isolated, and guest endpoints had previously accessed the internal network, creating unauthorized access risks.
- Endpoint security policies were inconsistent across departments, patch updates were delayed, and high-risk vulnerabilities persisted over time.
These problems revealed systemic deficiencies in the company’s endpoint security and data integrity management. Traditional “patch-style” remediation could no longer cope with increasingly stringent regulatory requirements and increasingly complex security threats. As a result, the company introduced the Ping64 integrated office security platform to unify governance over endpoints, software, data, behavior, and the network.
How Ping64 Helps the Pharmaceutical Industry Build a Compliance and Security Foundation
Ping64 does not simply stack security features. Instead, it addresses the pharmaceutical industry’s core needs—data integrity, audit trails, controlled permissions, and traceable behavior—by delivering integrated, verifiable, and auditable security management capabilities.
1. Unified Visibility of Endpoint Assets and Software Compliance for Validation and Audit Requirements
A pharmaceutical company’s software environment must be “known, verifiable, and controllable.” Ping64 automatically discovers and manages all endpoints across the network, collecting key data such as hardware information, operating system versions, patch status, installed software and versions, and installation sources.
Through a single console, administrators can view the software inventory of every endpoint and identify unauthorized, unvalidated, or pirated software. Combined with blacklist and whitelist policies, companies can clearly define the scope of “allowed to run” software, ensuring that GxP-related endpoints run only validated software versions and eliminating compliance risks caused by unvalidated software at the source.
2. Full Audit of Peripherals and File Transfers to Safeguard Data Integrity
Data integrity is a top priority for pharmaceutical industry regulation. Ping64 provides fine-grained control over endpoint peripherals such as USB drives, printers, and optical drives, with flexible authorization by department, role, and time, as well as complete records of peripheral read and write operations.
For critical data such as electronic lab notebook entries, chromatography data, and formulation files, Ping64 offers file transfer auditing: it records file creation, modification, copying, deletion, renaming, and external transfer, creating a tamper-proof audit trail. When the system detects sensitive files being copied to a USB drive, sent through instant messaging tools, or uploaded to personal cloud storage, it can block the operation in real time, raise an alert, and preserve evidence—ensuring that critical data cannot be taken out, altered, or denied.
3. Screen Watermarking and Behavior Auditing to Strengthen Data Leak Traceability
The pharmaceutical industry involves large amounts of R&D secrets and patient privacy. Data leaks not only cause commercial losses but may also violate regulations such as the Personal Information Protection Law and HIPAA. Ping64 supports screen watermarking, displaying user identity information on endpoint desktops to deter photo-based leaks and quickly locate the source when a leak occurs.
At the same time, Ping64 provides screen recording and behavior auditing capabilities. High-risk operations such as accessing core systems, exporting data in bulk, or modifying system configurations can be recorded according to policy, providing a visual evidence chain for security investigations and regulatory audits.
4. Dynamic Linkage Between Permissions and Network Access Control to Build a Controlled Access Environment
Pharmaceutical companies must strictly isolate R&D networks, production networks, and office networks, and endpoint access must be controlled. Ping64 provides network access control (NAC) that is dynamically linked with endpoint security status and software compliance status:
- Before an endpoint connects, it automatically checks the security baseline, such as whether designated antivirus software is installed, whether critical patches are applied, and whether unauthorized software is running.
- Non-compliant endpoints are automatically quarantined to a remediation zone and can only reconnect after remediation is complete.
- Network access permissions are dynamically adjusted based on endpoint risk status. For example, when a high-risk vulnerability is detected, access to core business systems is automatically restricted.
This dynamic linkage mechanism ensures that only “trusted and compliant” endpoints can access critical business resources, meeting GxP requirements for controlled permissions and environment isolation.
5. Automated Response and Compliance Reporting to Confidently Handle Regulatory Inspections
Pharmaceutical companies frequently face unannounced inspections and regular audits from regulators such as the FDA and NMPA. Ping64 has a built-in automated response engine that can preset handling actions for violations, such as:
- Unauthorized software detected running → automatically block the process and generate an alert.
- Sensitive file exfiltration detected → automatically disconnect the endpoint from the network and lock the screen.
- Endpoint fails to install patches on time → automatically push patches and restrict peripheral usage.
- Unauthorized device attempts to connect → automatically isolate it and record its MAC address.
In addition, Ping64 provides a unified visual reporting center. Endpoint security status, software compliance rates, data exfiltration trends, and alert handling records can all be exported with one click, generating reports that meet audit requirements. This greatly reduces the workload of preparing for inspections and makes compliance evidence readily available and trustworthy.
From “Passive Response” to “Proactive Compliance”: A Leap in Value
By deploying Ping64, the pharmaceutical company achieved systematic control over endpoint security and data integrity:
- R&D and laboratory endpoints: only validated software is allowed to run, all file transfers are audited, peripheral usage is controlled, and screen watermarks deter leaks.
- Production and quality control networks: strict access control with automatic isolation of non-compliant endpoints, and critical data is tamper-proof and traceable.
- Office and functional departments: software assets are clearly identified, unauthorized installations trigger real-time alerts, and sensitive file exfiltration is effectively blocked.
- IT and compliance departments: all endpoints are managed through a single console, reports are generated automatically, and audit response time is reduced from days to hours.
More importantly, this integrated control does not come at the cost of efficiency. Employees can self-install compliant software through an enterprise app store, request temporary permissions through online approval, and have security policies automatically delivered. The compliance path is clear and smooth, avoiding the “workarounds” and violations caused by overly restrictive controls.
Why Pharmaceutical Companies Choose Ping64
Digital security in the pharmaceutical industry is not a simple stacking of single-point tools; it requires a deeply integrated, auditable, and verifiable management system. The value of the Ping64 integrated office security platform lies in truly closing the loop across endpoint security, software compliance, data loss prevention, behavior auditing, network access control, and operational response. It makes “complete data, controlled permissions, traceable behavior, and preventable risks” not just a slogan, but a daily practice implemented on every endpoint, every file, and every operation.
Choosing Ping64 means choosing an integrated compliance and security foundation that covers endpoints, data, behavior, and networks, enabling pharmaceutical companies to move more steadily and further under the dual demands of strict regulation and high innovation.
Contact
9 min 
